RT期刊文章SR电子T1社区劣势和结果脑出血后神经学(S29.002)摩根富林明乔神经病学FD Lippincott Williams &威尔金斯SP 3607 10.1212 / WNL。首页0000000000203392签证官100 17补充2 A1 Jisoo金正日A1 Eva Kitlen A1维克多Torres-Lopez A1 Cyprien河A1 Daniela Renedo A1玛雅A1阿利亚jonkleinberg A1梅丽莎呸A1迈克尔Kampp A1莎拉Jasak A1劳伦sans A1凯文Sheth A1圭多要求年2023 UL //www.ez-admanager.com/content/100/17_Supplement_2/3607.abstract AB目的:我们旨在确定小区的劣势与贫穷有关脑出血后的结果(我)。首页背景:社区劣势独特捕获许多社会和环境风险。有越来越多的证据表明社会决定因素不同的健康状况。设计/方法:我们进行了一个嵌套的研究在一个正在进行的纵向研究,前瞻性地遵循脑损伤患者在康涅狄格最大的医疗体系。嵌套的研究包括我幸存者和评价社区剥夺剥夺使用面积指数(ADI),公开可用指标排名社区的劣势基于许多因素。病人被给予一个ADI tertile名称:低,中间,和高不足。最初我严重程度定义与gc的承认。结果是评估通过放电和6个月post-ICH改良Rankin规模(夫人),一分为二,0 - 3(结果)和4 - 6(可怜的结果)。我们使用卡方测试和未经调整和调整协会多变量逻辑回归分析,分别。结果:687注册我的病人,518年(平均年龄67,47.5%为女性,19%是黑人,8%的西班牙裔)有9-digit你和结果数据。 Neighborhood disadvantage was not associated with admission GCS (adjusted p=0.59) or discharge mRS (adjusted p=0.95). However, at 6-months post-discharge, the risk of poor outcome was 28%, 44%, and 47% for patients in neighborhoods with low, intermediate, and high disadvantage (unadjusted p=0.02). Multivariable analyses adjusting for potential confounders confirmed these results: compared to low-disadvantage neighborhoods, those living in neighborhoods with intermediate and high disadvantage had 52% (OR 1.52, 95%CI 0.76–3.08) and 89% (OR 1.89, 95%CI 0.91–3.94) higher risk of poor outcomes (test-for-trend p=0.01).Conclusions: Among ICH patients enrolled in a prospective study of acute brain injury, higher neighborhood disadvantage was associated with a higher risk of poor outcomes 6-months post-ICH but not with admission or discharge clinical status. These results suggest that the numerous factors captured by the ADI influence these subjects’ complex post-discharge evolution.Disclosure: Ms. Kim has nothing to disclose. Ms. Kitlen has nothing to disclose. Mr. Torres-Lopez has nothing to disclose. Dr. Rivier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pyxis Partners. Dr. Renedo has nothing to disclose. Ms. Schlechter has nothing to disclose. Ms. Kleinberg has nothing to disclose. Ms. Pish has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Twill Therapeutics. Mr. Kampp has nothing to disclose. Sara Jasak has nothing to disclose. Dr. Sansing has nothing to disclose. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care. The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.